NCT03131908View on ClinicalTrials.gov

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Melanoma and Other Malignant Neoplasms of SkinMetastatic Melanoma
Interventions
DRUG

GSK2636771

"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."

DRUG

Pembrolizumab

Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT03131908 - Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | Biotech Hunter | Biotech Hunter